2.1. Patients and Ethics Statement
impaired cognitive function, death, sarcopenia, malignant disease, cardiopulmonary insufficiency, renal insufficiency, neuropsychiatric disorders, sarcopenic femoral fractures, femoral fracture
SARCOPENIA, INFECTIOUS DISEASE, RENAL INSUFFICIENCY, DISEASES, MALIGNANT DISEASE
A total of 100 patients with sarcopenic femoral fractures were included in this study from January 2019 to January 2021 (age from 57 to 74 years old, 53 males and 47 females). The following are the inclusion criteria: (1) femoral fracture and received artificial joint replacement; (2) combined with sarcopenia; (3) aged 40-75 years; (4) mentally stable, able to communicate normally and to move independently, and voluntarily cooperate with this study. The following are the exclusion criteria: (1) complicated with severe cardiopulmonary insufficiency; (2) severe neuropsychiatric disorders; (3) inability to stand up independently; (4) impaired cognitive function; (5) severe renal insufficiency requires protein intake to be restricted; (6) patients with malignant disease or infectious disease; and (7) lost in the middle of the study, suffering from other diseases or death. All patients were informed about the study and signed the informed consent to join the study voluntarily. In addition, this study was a prospective study; the present study was approved and supervised by The Third Affiliated Hospital of Chongqing Medical University Hospital Ethics Committee.